Antifungal management

Intensive and Critical Care Medicine: WFSICCM World Federation of Societies of Intensive and Critical Care Medicine

Volumn , Issue , 2009, Pages 285-296

  Rinaldi, Simone ^a   De Gaudio, Angelo Raffaele ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892343648     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-88-470-1436-7_24     Document Type: Chapter

References (40)

1. Schelenz S (2008) Management of candidiasis in the intensive care unit. J Antimicrobial Chemother 61:i31-i34
2. Trof RJ, Beishuizen A, Debets-Ossenkopp YJ et al (2007) Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients. Intensive Care Med 33:1694-1703
3. Marie M, Oscar M, Thierry C (2008) Bench-to-bedside review: Candida infections in the intensive care unit. Crit Care 12:204
4. Leroy O, Gangneux JP, Montravers P et al for the Amar Cand Study Group (2009) Epidemiology, management, and risk factors for death of invasive candida infections in critical care: A multicenter, prospective, observational study in France (2005-2006). Crit Care Med 37(5):1612-1618
5. Fluit AC, Jones ME, Schmitz FJ et al (2000) Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis 30:454-460
6. Kibbler CC, Seaton S, Barnes RA et al (2003) Management and outcome of bloodstream infections due to Candida species in England and Wales. J Hosp Infect 54:18-24
7. Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E (2007) Invasive aspergillosis in the intensive care unit. Clin Infect Dis 45(2):205-216
8. Leon C, Ruiz-Santana S, Saavedra P et al (2006) A bedside scoring system (?Candida score?) for early antifungal treat ment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 34:730-737
9. Ostrosky-Zeichner L, Sable C, Sobel J et al (2007) Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 26:271-276
10. Pittet D, Monod M, Suter PM et al (1994) Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 220:751-758
11. Reiss E, Morrison CJ (1993) Nonculture methods for diagnosis of disseminated candidiasis. Clin Microbiol Rev 6:311-323
12. Bar W, Hecker H (2002) Diagnosis of systemic candida infections in patients of the intensive care unit. Significance of serum antigens and antibodies. Mycoses 45:22-28
13. Sendid B, Poirot JL, Tabouret M et al (2002) Combined detection of mannanamia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J Med Microbiol 51:433-442
14. Ostrosky-Zeichner L, Alexander BD, Kett DH et al (2005) Multicenter clinical evaluation of the (1,3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 41:654-659
15. Morace G, Pagano L, Sanguinetti M et al (1999) PCR-restriction enzyme analysis for detection of Candida DNA in blood from febrile patients with hematological malignancies. J Clin Microbiol 37:1871-1875
16. Ascioglu S, Rex JH, de Pauw B et al (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 34:7-14
17. Vandewoude KH, Blot SI, Depuydt P et al (2006) Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care 10:R31
18. Andreas S, Heindl S, Wattky C et al (2000) Diagnosis of pulmonary aspergillosis using optical brighteners. Eur Respir J 15:407-411
19. Greene R (2005) The radiological spectrum of pulmonary aspergillosis. Med Mycol 43:S147-S154
20. Ostrosky-Zeichner L, Alexander BD, Kett DH et al (2005) Multicenter clinical evaluation of the (1-3) beta-D glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 41:654-659
21. Digby J, Kalbfleisch J, Glenn A et al (2003) Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol 10:882-885
22. Raad I, Hanna H, Huaringa A et al (2002) Diagnosis of invasive pulmonary aspergillosis using polymerase chain reaction-based detection of Aspergillus in BAL. Chest 121:1171-1176
23. Playford EG, Eggimann P, Calandra T (2008) Antifungals in the ICU. Curr Opin Infect Dis 21:610-619
24. Noskin GA, Pietrelli L, Coffey G et al (1998) Amphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patients. Clin Infect Dis 26:461-467
25. Rex JH, Bennett JE, Sugar AM et al (1994) A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 331:1325-1330
26. Pfaller MA, Diekema DJ, Gibbs DL et al (2007) Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 45:1735-1745
27. Kullberg BJ, Sobel JD, Ruhnke M et al (2005) Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: A randomised noninferiority trial. Lancet 366:1435-1442
28. Vazquez JA, Skiest DJ, Nieto L et al (2006) A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 42:1179-1186
29. Wilcox CM, Darouiche RO, Laine L et al (1997) A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis 176:227-232
30. Gauthier GM, Nork TM, Prince R et al (2005) Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis 41:e27-e28
31. Mora-Duarte J, Betts R, Rotstein C et al (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347:2020-2029
32. Morrell M, Fraser VJ, Kollef MH (2005) Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. Antimicrob Agents Chemother 49:3640-3645
33. Garey KW, Rege M, Pai MP et al (2006) Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infects Dis 43:25-31
34. Ayeni O, Riederer KM, Wilson FM, Khatib R (1999) Clinicians? reaction to positive urine culture for Candida organisms. Mycoses 42(4):285-289
35. Garey KW, Neuhauser MM, Bearden DT et al (2006) Evaluation of antifungals in the surgical intensive care unit: a multiinstitutional study. Mycoses 49:226-231
36. Pfaller MA, Diekema DJ, Jones RN et al (2001) International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 39:3254-3259
37. Pappas PG, Rex JH, Sobel JD et al (2004) Guidelines for treatment of candidiasis. Clin Infect Dis 38:161-189
38. Bohme A, Ruhnke M, Buchheidt D et al (2003) Treatment of fungal infections in hematology and oncology - Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 82:S133-S140
39. Herbrecht R, Denning DW, Patterson TF et al (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408-415
40. Fluckiger U, Marchetti O, Bille J et al (2006) Treatment options of invasive fungal infections in adults. Swiss Med Wkly 136:447-463